Core Viewpoint - The company, Maiwei (Shanghai) Biotechnology Co., Ltd., reported a significant increase in revenue for 2024, driven by its commercialized products and technical services, while facing challenges in market penetration and competition in the biopharmaceutical sector [3][21]. Financial Performance - In 2024, the company achieved a revenue of 200 million RMB, representing a year-on-year growth of 56.28% [3]. - The revenue breakdown includes 145 million RMB from antibody drugs and 55 million RMB from technical services [3]. - The sales volume of the product Junmaikang decreased by 66.61% year-on-year, with a total shipment of 48,821 units [3][10]. Product Analysis - The company has three commercialized products: Junmaikang, Mailishu, and Maiweijian, with detailed sales revenue, costs, and gross margins provided [3][5]. - Junmaikang's sales revenue for 2024 was 124.37 million RMB, with a gross margin of 6.25% [5]. - Mailishu's sales revenue was 145.94 million RMB, with a gross margin of 86.87% [5]. - Maiweijian's sales revenue reached 145.92 million RMB, with a gross margin of 78.47% [5]. Market Dynamics - The TNF-α drug market in China grew from 3.5 billion RMB in 2019 to 10.1 billion RMB in 2023, with a projected growth to 42.9 billion RMB by 2032 [7]. - The competitive landscape for Junmaikang is challenging, with multiple similar products already in the market, leading to a decline in its sales volume [9][10]. Strategic Adjustments - The company is optimizing its regional operating model to improve efficiency and resource utilization, transitioning from self-operated sales to cooperative sales in underperforming areas [10][21]. - The company plans to expand the indications for Maiweijian to enhance its market competitiveness and sales revenue [25][21]. Research and Development - The company has several products in the pipeline, with multiple candidates entering Phase III clinical trials, expected to launch between 2028 and 2031 [20][21]. - The company is actively pursuing international collaborations and market expansions, particularly in emerging markets [26][27]. Technical Services - The technical service revenue composition includes significant contracts with major clients, contributing to the overall revenue [15][19]. - The company has received substantial payments for milestone achievements in its technical service agreements [15].

证券代码：688062 证券简称：迈威生物 公告编号：2025-024 问题一 关于经营业绩 1 主要客户、服务内容、合同对价、交付进展、收入确认进度及依据、销售回款 情况等。（4）结合营业收入分季度波动情况，说明第四季度营业收入环比增长 超 100%的原因及合理性。（5）结合公司主要在研产品的研发进度、预计上市 时间、预计销售规模等，说明公司是否存在亏损扩大风险，以及公司拟采取的 提高经营质效措施。 关于经营业绩。年报显示，2024 年公司实现营业收入 2.00 亿元，同比增长 56.28%，具体为抗体药物收入 1.45 亿元，技术服务收入 0.55 亿元。药物销售 方面，公司已有君迈康、迈利舒、迈卫健等 3 款产品获批上市，其中君迈康全 年发货 48,821 支，同比下降 66.61%，迈卫健全年发货 12,530 支，累计准入医 院 75 家。请你公司：（1）分产品列示公司三款商业化产品的销售收入、成本、 毛利率，并分析变动情况及原因。（2）结合市场需求、竞争格局、竞品销售情 况、价格成本波动等因素，分别说明君迈康发货量大幅下降、迈卫健医院准入 进度较慢的原因，分析是否符合行业趋势，并补充说明公司拟采取 ...

国泰海通证券股份有限公司 关于迈威（上海）生物科技股份有限公司 2024 年报告的信息披露监管问询函的专项核查意见 上海证券交易所： 根据贵所《关于迈威（上海）生物科技股份有限公司2024年报告的信息披 露监管问询函》（上证科创公函【2025】0064号）（以下简称"《问询函》"） 的要求，国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"） 作为迈威（上海）生物科技股份有限公司（以下简称"公司"）首次公开发行 股票并在科创板上市的保荐机构及持续督导机构，对问询函相关问题进行了审 慎核查，并出具核查意见如下： 本核查意见中若出现总计数尾数与所列数值总和尾数不符的情况，均为四 舍五入所致。本核查意见中所列示的包括但不限于收入、利润及产能规划等数 据的相关测算和预计均不构成业绩承诺或盈利预测。如无特别说明，本核查意 见中使用的简称或名词释义与《迈威（上海）生物科技股份有限公司2024年年 度报告》（以下简称"2024年报"）一致。 问题一 关于经营业绩 关于经营业绩。年报显示，2024 年公司实现营业收入 2.00 亿元，同比增长 56.28%，具体为抗体药物收入 1.45 亿元，技术服务收入 0.55 ...

就上海证券交易所科创板公司管理部 《关于对迈威(上海)生物科技股份有限公司2024年报告的信息披露监管问询函》 中部分涉及财务报表项目问询意见的专项说明 年报显示，2024年公司实现营业收入2.00亿元，同比增长56.28%，具体为抗体药物收入1.45亿元， 技术服务收入0.55亿元。药物销售方面，公司已有君迈康、迈利舒、迈卫健等3款产品获批上市，其中 君迈康全年发货48,821支，同比下降66.61%，迈卫健全年发货12,530支，累计准入医院75家。请你公 司：（1）分产品列示公司三款商业化产品的销售收入、成本、毛利率，并分析变动情况及原因。（2） 结合市场需求、竞争格局、竞品销售情况、价格成本波动等因素，分别说明君迈康发货量大幅下降、 迈卫健医院准入进度较慢的原因，分析是否符合行业趋势，并补充说明公司拟采取的改进措施。（3） 说明公司技术服务收入的具体构成，包括但不限于技术服务收入对应的主要客户、服务内容、合同对 价、交付进展、收入确认进度及依据、销售回款情况等。（4）结合营业收入分季度波动情况，说明第 四季度营业收入环比增长超 100%的原因及合理性。（5）结合公司主要在研产品的研发进度、预计上 市时 ...

A股生物制品板块短线拉升，三生国健涨超10%，诺诚健华、荣昌生物、迈威生物、凯因科技、智翔金 泰等跟涨。 ...

Group 1 - The innovative pharmaceutical ETF (560900) has seen a 0.89% increase, marking a four-day rising streak, with the index tracking the innovative drug industry (931152) up by 0.85% [1] - Notable stock performances include Maiwei Biotech (688062) rising over 9%, Tianshili (600535) up 4.76%, and Baotai (688177) increasing by 4.38% [1] - The innovative pharmaceutical ETF has experienced a significant growth of 4 million shares in the last three months, indicating a recovery in market enthusiasm for the pharmaceutical sector [2] Group 2 - The pharmaceutical and biotechnology sector's Q1 2025 financial reports show stable revenue and profit performance, with notable improvements in certain sub-industries [2] - The market sentiment towards the pharmaceutical sector has shifted positively, ending a continuous downtrend since Q1 2024, driven by a systematic valuation increase in the innovative drug sector [2] - Long-term potential exists in China's biomanufacturing, quantum technology, embodied intelligence, and 6G industries, with significant development opportunities across the entire industrial chain [2] Group 3 - Morgan Asset Management is integrating its "Global Vision Investment Technology" product line to assist investors in seizing investment opportunities in quality technology companies globally [2] - Various actively managed funds focus on emerging industry trends, including the Morgan Emerging Power Fund and the Morgan Smart Connectivity Fund, which targets artificial intelligence opportunities [3] - The Morgan Hang Seng Technology ETF and the Morgan Zhongzheng Innovative Pharmaceutical Industry ETF provide passive investment options for technology and innovative pharmaceutical sectors [3]

Group 1 - The core viewpoint is that the China Securities Regulatory Commission (CSRC) is expediting a comprehensive policy package to deepen reforms in the Sci-Tech Innovation Board and the Growth Enterprise Market, aiming to enhance the scale and proportion of medium to long-term capital entering the market [1] - The People's Bank of China and four other departments are implementing policies to support technological innovation, encouraging financial institutions to expand first-time financing and equipment renewal loans for tech companies [1] - Guoyuan Securities believes that under high global technological barriers, companies on the Sci-Tech Innovation Board are pursuing independent innovation across various sectors, including chip design, biomedicine, high-end equipment, and new energy, positioning themselves as pioneers in the international value chain [1] Group 2 - As of April 30, 2025, the top ten weighted stocks in the Sci-Tech Innovation Board 100 Index account for 25.04% of the index, with companies like Hengxuan Technology and BeiGene among the leaders [2] - The Sci-Tech 100 ETF fund has shown a positive performance, with notable increases in the stock prices of several constituent companies, indicating a favorable market sentiment [1]

Group 1 - The A-share market saw a collective decline on May 16, while the Sci-Tech Innovation Pharmaceutical sector rebounded, with the Sci-Tech Innovation Pharmaceutical ETF (588860) rising by 0.16% [1] - Notable stocks in the sector included Maiwei Biotech-U, which increased by over 5%, along with Shouyao Holdings-U, KQ Biotech, Innotec, CanSino, and Baotai, all of which experienced gains [1] - The Sci-Tech Innovation Pharmaceutical ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which selects 50 large-cap companies in biopharmaceuticals and related fields to reflect the overall performance of representative companies in the sector [1] Group 2 - According to CMB International, the optimization of centralized procurement policies in mainland China provides hospitals and enterprises with more flexibility and autonomy, benefiting leading prescription drug companies [2] - The anticipated implementation of favorable policies, such as the 2025H2 medical insurance category, is expected to accelerate industry consolidation, with the sector's valuations remaining at historical lows [2] - The recommendation is to focus on innovative drug targets with high growth potential or clear breakeven timelines after short-term sentiment stabilizes [2]

Core Viewpoint - The company is facing significant challenges, including an investigation into its chairman for alleged short-term trading, high debt levels, and a critical need for funding as it pursues an IPO in Hong Kong [2][5]. Group 1: Company Background and Financial Situation - The company was founded in 2017 by Liu Datao and Tang Chunshan, with a focus on innovative drugs during a capital influx period [3]. - The company has received approval for three drugs but has not yet turned a profit, reporting a revenue of 0.45 billion yuan in Q1 2024, a 33.7% decrease year-on-year, and a net loss of 2.92 billion yuan, widening from a loss of 2.06 billion yuan in the same period of 2023 [3][4]. - As of Q1 2024, the company had cash reserves of 1.12 billion yuan and short-term loans of 1.073 billion yuan, with a debt ratio exceeding 60% [5]. Group 2: Capital Needs and IPO Plans - The company has initiated the process for a Hong Kong IPO to meet its funding needs and enhance its international presence [6]. - In March 2024, the company planned to issue up to 500 million yuan in targeted debt financing to optimize its debt structure and reduce financial costs [6]. Group 3: Management Changes and Strategic Moves - Significant management changes have occurred, including the appointment of Liu Datao as chairman and the departure of key personnel such as Zhang Jinchao, who was responsible for antibody drug development [7]. - The company has entered into a supplemental agreement with Junshi Biosciences regarding the commercialization of its drug Junmai Kang, which has seen a 149.77% increase in sales to 44.72 million yuan in Q1 2024 [8]. Group 4: Market Position and Future Prospects - The company is currently valued at approximately 7 billion yuan, nearly halving from its initial valuation of 13.9 billion yuan at the time of listing [10]. - The company is focusing on the clinical progress of its lead product 9MW2821, which targets Nectin-4 and competes with a product from Ansai Pharmaceutical [9].

Core Viewpoint - The company is facing a governance crisis due to the chairman's investigation for suspected short-term trading, which has raised concerns about its financial stability and ongoing IPO plans [2][3][17]. Financial Performance - The company has not achieved profitability since its establishment, with cumulative losses exceeding 6 billion yuan by the first quarter of 2025 [4][11]. - The net profit for 2022, 2023, and 2024 was reported as -9.55 billion yuan, -10.53 billion yuan, and -10.44 billion yuan respectively, totaling over 3 billion yuan in losses [4]. - In the first quarter of 2025, the company reported a revenue of 44.79 million yuan, a 33.70% decrease year-on-year, with a net profit of -291.73 million yuan, a 41.85% decline from the previous year [6][10]. R&D Investment - The company has maintained a high R&D investment ratio, with R&D expenses accounting for 2735.89%, 653.79%, and 391.86% of revenue in the past three years, indicating a significant imbalance between R&D spending and revenue generation [4][5]. - In the first quarter of 2025, R&D expenses represented 465.62% of revenue, highlighting severe delays in commercialization [5][8]. Product Commercialization - The company has three commercialized products, but their combined sales revenue was only 2 billion yuan in 2024, which is considered low for the industry [11][12]. - The core issues affecting sales performance are identified as weak commercialization capabilities rather than product competitiveness, necessitating improvements in marketing and sales strategies [11][12]. Acquisition Strategy - The company has pursued an aggressive acquisition strategy, acquiring multiple subsidiaries since its inception, leading to a rapid increase in fixed assets, which reached 1.653 billion yuan by the end of 2024 [12][14]. - However, most of these subsidiaries have not been profitable, contributing to the overall financial burden of the company [12][14]. IPO Prospects - The ongoing investigation of the chairman may complicate the company's IPO process, potentially leading to stricter regulatory scrutiny and delays [17]. - The company asserts that the investigation will not significantly impact its IPO plans, but the outcome of the investigation could affect investor confidence and financing capabilities [17].